MORE►
Nanoscope Therapeutics
Paul Hallen will oversee Nanoscope's global operations, including commercial readiness, supply chain, and cross-functional execution, as the company works toward regulatory approval and launch of MCO-010 (MOGENRY), a therapy developed to treat retinitis pigmentosa.
Nanoscope Therapeutics Names Former Alcon Exec as Its New COO
by Sandra Engelland | Apr 2, 2026
Paul Hallen will oversee Nanoscope's global operations, including commercial readiness, supply chain, and cross-functional execution, as the company works toward regulatory approval and launch of MCO-010 (MOGENRY), a therapy developed to treat retinitis pigmentosa.
by Dallas Innovates | Staff Report |
Dec 10, 2025
Dallas-Fort Worth ranked No. 9 for patent activity out of 250 metros for the week of Nov. 4 with a total of 156 patents granted.
MORE►
by Quincy Preston |
Jul 15, 2025
North Texas' Nanoscope just filed an FDA bid for its gene-agnostic therapy. If approved, it could help restore sight for people with inherited blindness, and potentially millions more with other retinal diseases.
MORE►
by Lance Murray |
Dec 6, 2024
Ray Kaczmarek—the former CEO of Genezen—is an expert in gene therapy manufacturing with decades of experience leading operations, technology, and commercial supply strategies at pharmaceutical and biotech companies, Nanoscope said.
MORE►
Health Wildcatters co-founder and CEO Hubert Zajicek [Image: Courtesy Health Wildcatters]
The Last Word: Health Wildcatters’ Dr. Hubert Zajicek on Dallas’ Biotech Boom
by Dallas Innovates | Staff Report | Apr 4, 2023
Dr. Zajicek and three other local biotech leaders—Sulagna Bhattacharya, CEO of Nanoscope Therapeutics; Gabby Everett, director of business operations and strategy at BioLabs Pegasus Park; and R.A. Session II, founder of Taysha Gene Therapies—discussed Dallas' biotech boom on a panel hosted by D CEO Healthcare.
MORE►
by Quincy Preston |
Mar 16, 2023
These standouts—startup founders, tech pioneers, educators, creators, social innovators, and business leaders—are transforming entire industries and making waves in their respective fields.
MORE►
by Quincy Preston |
Mar 16, 2023
Meet the startup innovators who are driving change in their industries and beyond. These startups are among the Future 50 in Dallas-Fort Worth, our editors’ picks of forward-thinking innovators who are shaping their industries and communities.
From the healthcare sector to the real estate industry, these trailblazers are disrupting the status quo with their groundbreaking technologies and solutions....
MORE►
by Dallas Innovates | Staff Report |
Mar 1, 2023
Dallas-Fort Worth is well known for its tech expertise. Now it being recognized as the place where technology meets life science—a convergence that’s driving rapid growth in the biotech ecosystem....
MORE►
Jean Chang and Victor Adeniyi [Nanoscope Therapeutics]
Nanoscope Therapeutics Adds 2 Execs to Chemistry, Manufacturing, Controls Team
by Lance Murray | Nov 11, 2022
Dallas-based Nanoscope Therapeutics is developing therapies that could restore sight in patients. The company also recently announced a new gene therapy manufacturing partnership.
MORE►
by Kevin Cummings |
Oct 18, 2022
Dallas-based Nanoscope Therapeutics is accelerating the development of therapies that could restore sight in patients with the help of a publicly traded firm. The retinal degenerative diseases-focused biotech company announced a new gene therapy manufacturing partnership with contract research organization Charles River Laboratories International.
MORE►
by Dallas Innovates | Staff Report |
Sep 7, 2022
Every year, Tech Titans highlights the top movers and shakers in the North Texas technology ecosystem. Here are the finalists in 11 categories. Winners will be announced at the group's signature gala in October.
MORE►
Meet the Finalists: The Innovation Awards 2022, Presented by Dallas Innovates and D CEO
by Dallas Innovates | Staff Report | Oct 26, 2021
Now in its third year, the program from Dallas Innovates and D CEO honors 78 disruptors and trailblazers driving a new vision for innovation in North Texas.
MORE►
by Alex Edwards |
Sep 14, 2021
The Bedford-based biotech will use the capital from the National Eye Institute of the National Institutes of Health to advance its gene therapy that treats age-related macular degeneration.
Earlier this summer, Nanoscope Therapeutics announced it successfully treated 11 patients who were blinded by advanced retinitis pigmentosa.
Earlier this summer, Nanoscope Therapeutics announced it successfully treated 11 patients who were blinded by advanced retinitis pigmentosa.
MORE►
by David Seeley |
Jun 22, 2021
Nanoscope Therapeutics successfully treated 11 patients blinded by advanced retinitis pigmentosa (RP). A single intravitreal injection produced positive results that persisted through one year. The startup plans a Phase 2b trial this summer and plans to develop gene therapies to treat more common retinal diseases—like dry age-related macular degeneration.
MORE►
by Lauren Hawkins |
Jul 21, 2020
Nanoscope Therapeutics, a TechFW client, has closed an over-subscribed Series A funding round for its leading work on retinas, which could enable the blind to see.
In addition, Nanoscope has named Al Guillem as Chairman of the Board. Guillem (pictured below) was part of TechFW's greatest success story when ZS Pharma, a company he co-founded, was purchased by AstraZeneca for $2.7 billion.
In addition, Nanoscope has named Al Guillem as Chairman of the Board. Guillem (pictured below) was part of TechFW's greatest success story when ZS Pharma, a company he co-founded, was purchased by AstraZeneca for $2.7 billion.
MORE►
